Astrazeneca annual total assets
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Astrazeneca Total Assets Growth & History (AZN)
Astrazeneca's total assets was $114.07B for fiscal 2025.
View full Astrazeneca company overviewAstrazeneca annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $114.07B | $10.04B | +9.65% |
| 2024 | 2024-12-31 | $104.03B | $2.92B | +2.88% |
| 2023 | 2023-12-31 | $101.12B | $4.64B | +4.80% |
| 2022 | 2022-12-31 | $96.48B | −$8.88B | −8.43% |
| 2021 | 2021-12-31 | $105.36B | $38.63B | +57.90% |
| 2020 | 2020-12-31 | $66.73B | $5.35B | +8.72% |
| 2019 | 2019-12-31 | $61.38B | $726.0M | +1.20% |
| 2018 | 2018-12-31 | $60.65B | −$2.70B | −4.27% |
| 2017 | 2017-12-31 | $63.35B | $828.0M | +1.32% |
| 2016 | 2016-12-31 | $62.53B | $2.47B | +4.11% |
| 2015 | 2015-12-31 | $60.06B | — | — |
Astrazeneca quarterly total assets
Q4.17
Q2.18
Q4.18
Q2.19
Q4.19
Q2.20
Q4.20
Q2.21
Q4.21
Q2.22
Q4.22
Q2.23
Q4.23
Q2.24
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $115.83B | $3.41B | +3.03% |
| Q1 2026 | 2026-03-31 | $114.02B | — | — |
| Q4 2025 | 2025-12-31 | $114.07B | $10.04B | +9.65% |
| Q3 2025 | 2025-09-30 | $114.46B | — | — |
| Q2 2025 | 2025-06-30 | $112.42B | $8.08B | +7.75% |
| Q4 2024 | 2024-12-31 | $104.03B | $2.92B | +2.88% |
| Q2 2024 | 2024-06-30 | $104.34B | $7.80B | +8.08% |
| Q4 2023 | 2023-12-31 | $101.12B | $4.64B | +4.80% |
| Q2 2023 | 2023-06-30 | $96.54B | −$36.0M | −0.04% |
| Q4 2022 | 2022-12-31 | $96.48B | −$8.88B | −8.43% |
| Q2 2022 | 2022-06-30 | $96.58B | $22.94B | +31.15% |
| Q4 2021 | 2021-12-31 | $105.36B | $38.63B | +57.90% |
| Q2 2021 | 2021-06-30 | $73.64B | $13.71B | +22.88% |
| Q4 2020 | 2020-12-31 | $66.73B | $5.35B | +8.72% |
| Q2 2020 | 2020-06-30 | $59.93B | −$1.96B | −3.17% |
| Q4 2019 | 2019-12-31 | $61.38B | $726.0M | +1.20% |
| Q2 2019 | 2019-06-30 | $61.89B | $545.0M | +0.89% |
| Q4 2018 | 2018-12-31 | $60.65B | −$2.70B | −4.27% |
| Q2 2018 | 2018-06-30 | $61.34B | — | — |
| Q4 2017 | 2017-12-31 | $63.35B | — | — |
Astrazeneca total assets trends
Over the last five fiscal years, Astrazeneca's total assets increased from $66.73B to $114.07B, a change of $47.34B. The latest reported quarter, Q2 2026, shows $115.83B.
About the metric
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
Calculation and source
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Astrazeneca source filings ↗Community posts
AstraZeneca receives US accelerated approval for Etcamah in a defined breast-cancer setting
AstraZeneca announced US accelerated approval of Etcamah on 7 September 2026. Approved setting Camizestrant, combined with a CDK4/6 inhibitor, is approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast canc ...